Cinda Securities released a research report on April 27 stating that it gave Sunflower Pharmaceutical (002737.SZ) an increase in holdings rating. The main reasons for the rating include: 1) completing the “Fifth Five-Year Plan” with excellent performance, with a proposed dividend ratio of about 78% in 2023; 2) the “buy, reform, cooperation, research and generation” strategy to create the company's second driving force for growth; 3) 2024Q1's high base put pressure on 2024Q1 performance, and the “Sixth Five-Year Plan” began a new journey. (Mainichi Keizai Shimbun)
信达证券4月27日发布研报称，给予葵花药业（002737.SZ）增持评级。评级理由主要包括：1）以优秀业绩完成“五五”规划，2023年拟分红比例约78%；2）“买、改、联、研、代”策略打造公司第二成长驱动力；3）2023Q1高基数致使2024Q1业绩承压，“六五”规划启动新征程。（每日经济新闻）
Cinda Securities released a research report on April 27 stating that it gave Sunflower Pharmaceutical (002737.SZ) an increase in holdings rating. The main reasons for the rating include: 1) completing the “Fifth Five-Year Plan” with excellent performance,
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.